Literature DB >> 29445190

The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.

Qiong Wu1, Jin-Xian Chen2, Yu Chen1, Li-Li Cai1, Xiao-Zhong Wang1, Wu-Hua Guo3, Jian-Feng Zheng4,5.   

Abstract

G-protein-coupled receptor (GPCR)-related proteins are dysregulated and the GPCR CC-chemokine receptor 10 (CCR10) is significantly upregulated in inflammation-driven HCC. However, CCR10's role in inflammation-driven hepatocarcinogenesis remains unknown. The aim of this study was to evaluate the role of CCR10 in inflammation-driven hepatocarcinogenesis. Via a targeted gene expression microarray screening alterations in GPCR family gene expression, we found CCR10 to be significantly upregulated in hepatocytes isolated from inflammation-driven human HCC tumors and matching paracancerous tissues. Tetrachloromethane (CCl4)-induced and diethylnitrosamine (DEN)-induced murine models of inflammatory hepatocarcinogenesis displayed significant hepatocellular TNF and CCR10 upregulation. Exogenous TNF applied to HepG2 and LO2 cell lines as well as wild-type (WT) mice significantly upregulated hepatocellular CCR10 expression, Akt phosphorylation, PCNA expression, and hepatocellular proliferation. Additionally, exogenous TNF significantly upregulated secretion of the natural CCR10 ligand-agonist CCL28 from both cell lines. Transgenic CCR10-knockout (CCR10 KO) in DEN-treated mice significantly increased hepatocellular apoptosis levels and significantly lowered compensatory hepatocellular proliferation but did not affect upstream TNF expression. In addition, DEN-treated CCR10 KO mice showed a significantly lower liver weight/body weight ratio, significantly lower liver tumor incidence, and significantly smaller tumors. Moreover, exogenous CCR10 expression significantly raised xenograft tumor growth in Balb/c nude mice. In vitro, CCR10 transfection or CCL28 treatment in HepG2 and LO2 cell lines significantly increased Akt phosphorylation, PCNA expression, and cell proliferation, while CCR10 silencing or Akt inhibition produced the opposite effects. In vivo, hepatocytes isolated from HCC tumor tissue and matching paracancerous tissue in DEN-treated CCR10 KO mice showed significantly lower Akt phosphorylation and PCNA expression relative to WT hepatocytes. In conclusion, inflammation-induced TNF promotes hepatocellular CCR10 expression and downstream PI3K/Akt-mediated hepatocarcinogenesis. CCR10 appears to function as a linkage between TNF stimulation and downstream PI3K/Akt pathway activation and shows promise as a potential therapeutic target for inflammation-driven HCC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29445190      PMCID: PMC5833857          DOI: 10.1038/s41419-018-0267-9

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


  33 in total

Review 1.  Dissection of aberrant GPCR signaling in tumorigenesis--a systems biology approach.

Authors:  Jinhua Wu; Na Xie; Xia Zhao; Edouard C Nice; Canhua Huang
Journal:  Cancer Genomics Proteomics       Date:  2012-01       Impact factor: 4.069

2.  DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27.

Authors:  Hekla Sigmundsdottir; Junliang Pan; Gudrun F Debes; Carsten Alt; Aida Habtezion; Dulce Soler; Eugene C Butcher
Journal:  Nat Immunol       Date:  2007-01-28       Impact factor: 25.606

3.  Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation.

Authors:  A Wree; C D Johnson; J Font-Burgada; A Eguchi; D Povero; M Karin; A E Feldstein
Journal:  Cell Death Differ       Date:  2015-04-24       Impact factor: 15.828

4.  Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma.

Authors:  Kazuaki Nakanishi; Michiie Sakamoto; Susumu Yamasaki; Satoru Todo; Setsuo Hirohashi
Journal:  Cancer       Date:  2005-01-15       Impact factor: 6.860

5.  Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape.

Authors:  Oriana Simonetti; Gaia Goteri; Guendalina Lucarini; Alessandra Filosa; Tiziana Pieramici; Corrado Rubini; Graziella Biagini; Annamaria Offidani
Journal:  Eur J Cancer       Date:  2006-04-27       Impact factor: 9.162

Review 6.  Obesity, inflammation, and liver cancer.

Authors:  Beicheng Sun; Michael Karin
Journal:  J Hepatol       Date:  2011-11-25       Impact factor: 25.083

7.  β-Arrestin1 enhances hepatocellular carcinogenesis through inflammation-mediated Akt signalling.

Authors:  Yidong Yang; Yunwei Guo; Siwei Tan; Bilun Ke; Jin Tao; Huiling Liu; Jie Jiang; Jianning Chen; Guihua Chen; Bin Wu
Journal:  Nat Commun       Date:  2015-06-16       Impact factor: 14.919

Review 8.  Hepatitis C virus-associated cancer.

Authors:  Ming V Lin; Lindsay Y King; Raymond T Chung
Journal:  Annu Rev Pathol       Date:  2014-11-05       Impact factor: 23.472

9.  Targeting PI3K Signaling in Cancer: A Cautionary Tale of Two AKTs.

Authors:  Jérôme Fortin; Tak W Mak
Journal:  Cancer Cell       Date:  2016-04-11       Impact factor: 31.743

10.  Hypoxia-induced CCL28 promotes recruitment of regulatory T cells and tumor growth in liver cancer.

Authors:  Li Ren; Yang Yu; Li Wang; Zhifeng Zhu; Rong Lu; Zhi Yao
Journal:  Oncotarget       Date:  2016-11-15
View more
  7 in total

1.  The bioinformatics and experimental analysis of the novel roles of virus infection-associated gene CDC20 for prognosis and immune infiltration in hepatocellular carcinoma.

Authors:  Juanni Li; Xiaofang Zhang; Lei Yao; Kuan Hu
Journal:  Aging (Albany NY)       Date:  2022-05-27       Impact factor: 5.955

2.  CCR10/CCL27 crosstalk regulates cell metastasis via PI3K-Akt signaling axis in non-small-cell lung cancer.

Authors:  Yonggang Liu; Ailian Xiao; Biyuan Zhang
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

Review 3.  Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy.

Authors:  Bin Wang; Qin Zhao; Yuyu Zhang; Zijing Liu; Zhuangzhuang Zheng; Shiyu Liu; Lingbin Meng; Ying Xin; Xin Jiang
Journal:  J Exp Clin Cancer Res       Date:  2021-01-09

4.  Role of chemokines in hepatocellular carcinoma (Review).

Authors:  Dongdong Xue; Ya Zheng; Junye Wen; Jingzhao Han; Hongfang Tuo; Yifan Liu; Yanhui Peng
Journal:  Oncol Rep       Date:  2020-12-22       Impact factor: 3.906

5.  Inhibition of anti-inflammatory pathway through suppressors of cytokine signalling (Socs2/Socs3) in the initiation of hepatocellular carcinoma.

Authors:  Isbah Ashfaq; Nadeem Sheikh; Naz Fatima; Asima Tayyeb
Journal:  Saudi J Biol Sci       Date:  2022-06-20       Impact factor: 4.052

6.  Guizhi Fuling Decoction inhibiting the PI3K and MAPK pathways in breast cancer cells revealed by HTS2 technology and systems pharmacology.

Authors:  Yifei Dai; Weijie Qiang; Xiankuo Yu; Siwei Cai; Kequan Lin; Lan Xie; Xun Lan; Dong Wang
Journal:  Comput Struct Biotechnol J       Date:  2020-05-18       Impact factor: 7.271

7.  ClC-3/SGK1 regulatory axis enhances the olaparib-induced antitumor effect in human stomach adenocarcinoma.

Authors:  Zhuoyu Gu; Liping Wang; Xiaohan Yao; Qian Long; Kaping Lee; Jieyao Li; Dongli Yue; Shuangning Yang; Yanfen Liu; Na Li; Yixin Li
Journal:  Cell Death Dis       Date:  2020-10-22       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.